---
title: "Harrow Health Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295281481.md"
description: "Harrow Health (HROW) will report Q2 2026 earnings on August 10 after market close. Consensus estimates project an EPS of -$0.24, down 200% year-over-year, and revenue of $70.35 million, up 10.4%. Historically, the company has beaten EPS estimates 50% of the time and revenue estimates 25% of the time over the past two years."
datetime: "2026-08-07T21:54:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295281481.md)
  - [en](https://longbridge.com/en/news/295281481.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295281481.md)
generator: "portal-rs"
---

# Harrow Health Q2 2026 earnings preview

Harrow Health (HROW) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. The consensus EPS Estimate is -$0.24 (-200.0% Y/Y) and the consensus Revenue Estimate is $70.35M (+10.4% Y/Y). Over the last 2 years, HROW has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. More on Ha...

### Related Stocks

- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)

## Related News & Research

- [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md)
- [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md)
- [TotalEnergies EP Gabon reports 4.5 million shares, 8.25 million voting rights as of July 31, 2026](https://longbridge.com/en/news/297217809.md)
- [National Bank of Canada declares quarterly dividend of $1.32 per share](https://longbridge.com/en/news/297027622.md)
- [HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline](https://longbridge.com/en/news/295473527.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**